GW Pharmaceuticals PLC Sponsored ADR
(NASDAQ : GWPH)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SHPGShire PLC Sponsored ADR
0.32%173.300.4%$142.80m
JAZZJazz Pharmaceuticals Plc
0.70%177.282.2%$125.36m
SAGESAGE Therapeutics, Inc.
-0.35%167.429.6%$116.12m
PRGOPerrigo Co. Plc
-0.55%76.006.7%$93.00m
ENDPEndo International Plc
0.22%11.248.9%$75.76m
MNKMallinckrodt Plc
0.92%22.0221.1%$73.41m
ICPTIntercept Pharmaceuticals, Inc.
0.43%96.0921.8%$69.04m
ZGNXZogenix, Inc.
-1.35%58.4011.9%$67.82m
GWPHGW Pharmaceuticals PLC Sponsored ADR
0.06%148.976.8%$63.42m
CTLTCatalent Inc
0.49%43.392.6%$62.41m
SUPNSupernus Pharmaceuticals, Inc.
-1.10%54.106.3%$40.45m
MDCOMedicines Company
0.63%40.0121.8%$39.34m
PTLAPortola Pharmaceuticals, Inc.
0.13%40.157.7%$37.37m
UTHRUnited Therapeutics Corporation
0.77%124.0814.4%$37.00m
AERIAerie Pharmaceuticals, Inc.
0.99%74.337.9%$32.19m

Company Profile

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. It operates through the following segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the commercial products and promotes Sativex through collaborations with pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex, which are using the proprietary cannabinoid technology platform. The company was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.